This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

abiraterone (Zytiga®)

Reference No. 3

Publication date:

Appraisal information

abiraterone (Zytiga®) 250 mg tablet

Company: Janssen-Cilag Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 04/01/2012
AWMSG meeting date: 08/02/2012
Submission Type: Full Submission
Status: Superseded
Advice No: 0612
Ratification by Welsh Government: 17/02/2012

Current Progress

Ratification by
Welsh Government

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA259). NICE GUIDANCE ISSUED JUNE 2012. (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology). Abiraterone (Zytiga®) with prednisone or prednisolone is recommended for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. This recommendation applies only in circumstances where the approved Wales Patient Scheme for access to medicines is utilised. AWMSG is of the opinion that abiraterone (Zytiga®) is suitable for specialist only prescribing within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
AWMSG Secretariat Appraisal Report (ASAR)
Clinical Expert (CE) Summary